{"id":6732,"date":"2022-06-20T11:01:14","date_gmt":"2022-06-20T09:01:14","guid":{"rendered":"https:\/\/covid-19-bilgi.de\/?page_id=6732"},"modified":"2022-11-29T14:36:30","modified_gmt":"2022-11-29T12:36:30","slug":"cocuk-asilari-5-11-yas","status":"publish","type":"page","link":"https:\/\/covid-19-bilgi.de\/tr\/cocuk-asilari-5-11-yas\/","title":{"rendered":"\u00c7ocuk A\u015f\u0131lar\u0131 5-11 ya\u015f"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

5 ila11 ya\u015f\u0131ndaki \u00e7ocuklar i\u00e7in<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Korona A\u015f\u0131s\u0131<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Neden 5 ila 11 ya\u015f\u0131ndaki \u00e7ocuklar da a\u015f\u0131lanmal\u0131d\u0131r?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Kas\u0131m 2021’de BioNTech\/Pfizer’in COVID-19 a\u015f\u0131s\u0131 AB genelinde 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklar i\u00e7in daha d\u00fc\u015f\u00fck bir dozda onaylanm\u0131\u015ft\u0131. Ba\u015flang\u0131\u00e7ta \u00e7ocuk a\u015f\u0131s\u0131 Daimi A\u015f\u0131 Komisyonu (STIKO) taraf\u0131ndan daha \u00e7ok \u00f6nceden hastal\u0131\u011f\u0131 olan \u00e7ocuklar i\u00e7in tavsiye etmi\u015fti. \u015eimdi STIKO 5 ya\u015f\u0131ndan itibaren t\u00fcm \u00e7ocuklar\u0131n a\u015f\u0131lanmas\u0131n\u0131 tavsiye etmektedir.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

BioNTech\/Pfizer’in 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklar i\u00e7in \u00fcretti\u011fi d\u00fc\u015f\u00fck dozlu Comirnaty\u00ae a\u015f\u0131s\u0131, 2021 Aral\u0131k ay\u0131n\u0131n ortas\u0131ndan bu yana Almanya’da kullan\u0131lmaktad\u0131r. 2 Mart 2022’de Avrupa Komisyonu, Moderna’n\u0131n 6 ya\u015f ve \u00fczeri \u00e7ocuklarda kullan\u0131lmak \u00fczere yar\u0131m doz COVID-19 a\u015f\u0131s\u0131 Spikevax\u00ae’\u0131 onaylam\u0131\u015ft\u0131r.<\/p>

\u00c7ocuk a\u015f\u0131lar\u0131 sayesinde art\u0131k 5 ya\u015f ve \u00fcst\u00fc k\u00fc\u00e7\u00fck \u00e7ocuklar da korona vir\u00fcs\u00fcnden korunabilmektedir. Bu \u00f6zellikle alt hastal\u0131klar\u0131 olan \u00e7ocuklar i\u00e7in \u00f6nemlidir, \u00e7\u00fcnk\u00fc ciddi bir COVID-19 hastal\u0131k seyri riski ta\u015f\u0131maktad\u0131rlar. Bu risk grubuna \u00f6rne\u011fin kalp yetmezli\u011fi, trizomi 21 veya \u015fiddetli obezitesi olanlar da dahildir. Almanya’da ya\u015flar\u0131 5 ile 11 aras\u0131nda olan bir milyondan fazla \u00e7ocuk bu imkandan yararlanarak a\u015f\u0131land\u0131lar.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

5 ila 11 ya\u015f\u0131ndaki \u00e7ocuklara yeti\u015fkinlerle ayn\u0131 a\u015f\u0131 m\u0131 kullan\u0131l\u0131yor?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Hay\u0131r, a\u015f\u0131 5 ila 11 ya\u015f\u0131ndaki \u00e7ocuklar i\u00e7in uyarlanm\u0131\u015ft\u0131r: Ergenler ve yeti\u015fkinler i\u00e7in BioNTech\/Pfizer a\u015f\u0131s\u0131n\u0131n aksine, yeni \u00e7ocuk a\u015f\u0131s\u0131 doz ba\u015f\u0131na sadece on mikrogram mRNA (aktif bile\u015fen) i\u00e7erir, yani 12 ya\u015f ve \u00fczerindeki ki\u015filere g\u00f6re dozdan (doz ba\u015f\u0131na 30 mikrogram) daha d\u00fc\u015f\u00fckt\u00fcr.\u00a0 2 Mart 2022’de Avrupa Komisyonu, Moderna’n\u0131n 6 ya\u015f ve \u00fczeri \u00e7ocuklarda kullan\u0131lmak \u00fczere yar\u0131m doz COVID-19 a\u015f\u0131s\u0131 Spikevax\u00ae’\u0131 (50 mikrogram mRNA) onaylam\u0131\u015ft\u0131r.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

STIKO 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklara ne tavsiye ediyor?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\u015eimdiye kadar mevcut olan t\u00fcm verileri de\u011ferlendiren STIKO, May\u0131s 2022’den itibaren a\u015fa\u011f\u0131daki \u00f6nerileri tavsiye etmektedir:<\/em>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
    \n \t
  • 5 ila 11 ya\u015f aras\u0131ndaki t\u00fcm \u00e7ocuklar ba\u015flang\u0131\u00e7ta yaln\u0131z bir kere olmak \u00fczere bir mRNA a\u015f\u0131s\u0131 ile \u2013 tercihen uyarlanm\u0131\u015f Comirnaty\u00ae 10 \u03bcg a\u015f\u0131s\u0131 ile a\u015f\u0131lanmal\u0131d\u0131r. Spikevax’\u0131n (50 \u03bcg) kullan\u0131m\u0131 6 ila 11 ya\u015f\u0131ndaki \u00e7ocuklar i\u00e7in de m\u00fcmk\u00fcnd\u00fcr.<\/li>
    \n \t
  • \u00d6nceden mevcut rahats\u0131zl\u0131klar\u0131 olan \u00e7ocuklara birincil ba\u011f\u0131\u015f\u0131klama (\u00fc\u00e7 ila alt\u0131 hafta arayla iki doz a\u015f\u0131) ve alt\u0131 ay sonra bir peki\u015ftirici a\u015f\u0131 yap\u0131lmal\u0131d\u0131r.<\/li>
    \n \t
  • STIKO, ciddi bir COVID-19 hastal\u0131\u011f\u0131na yakalanma riski ta\u015f\u0131yan ve kendi a\u015f\u0131lar\u0131 ile g\u00fcvenli bir \u015fekilde korunamayan ki\u015filerle (\u00f6rne\u011fin, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131flam\u0131\u015f ki\u015filer) yak\u0131n temasta olan (\u00f6nceden hastal\u0131\u011f\u0131 olmayan) \u00e7ocuklara \u00fc\u00e7 ila alt\u0131 hafta arayla iki doz a\u015f\u0131 \u00f6nermektedir.<\/li>
    \n \t
  • Ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklara – ba\u011f\u0131\u015f\u0131kl\u0131k eksikli\u011finin tipine ve ciddiyetine ba\u011fl\u0131 olarak – birincil ba\u011f\u0131\u015f\u0131klama i\u00e7in en az \u00fc\u00e7 doz a\u015f\u0131 yap\u0131lmal\u0131d\u0131r. Bu, \u00f6nceki a\u015f\u0131 dozundan en az d\u00f6rt hafta sonra yap\u0131lmal\u0131d\u0131r. Ayr\u0131ca STIKO, ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bask\u0131lanm\u0131\u015f \u00e7ocuklar i\u00e7in \u00f6nceki a\u015f\u0131 dozundan en az \u00fc\u00e7 ay arayla iki takviye a\u015f\u0131 \u00f6nermektedir.<\/li>
    \n \t
  • \u0130yile\u015fen \u00e7ocuklar enfeksiyondan \u00fc\u00e7 ay sonra a\u015f\u0131lanmal\u0131d\u0131r.<\/li>
    \n \t
  • Halihaz\u0131rda iki kez a\u015f\u0131lanm\u0131\u015f olan sa\u011fl\u0131kl\u0131 \u00e7ocuklara, ba\u015flang\u0131\u00e7ta ba\u015fka a\u015f\u0131lar yap\u0131lmamal\u0131d\u0131r.<\/li>\n<\/ul>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t\t
    <\/div>\n\t\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t
    <\/div>\n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    <\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Korona A\u015f\u0131s\u0131 \u0130le \u0130lgili G\u00fcncel Bilgileri Almanya\u2019n\u0131n Her Yerinden<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t

    0800 0000 837<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    No\u2019lu \u00dccretsiz T\u00fcrk\u00e7e Dan\u0131\u015fma Hatt\u0131ndan\u00a0alabilirsiniz.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    <\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    <\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    \u00c7ocuk a\u015f\u0131lar\u0131 ne kadar etkili ve g\u00fcvenli?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Onay \u00e7al\u0131\u015fmalar\u0131nda her iki \u00e7ocuk a\u015f\u0131s\u0131 da COVID-19 hastal\u0131\u011f\u0131 riskini etkili bir \u015fekilde azaltabilmi\u015f ve pozitif bir fayda-risk profili g\u00f6stermi\u015ftir. Buna g\u00f6re Comirnaty\u00ae (10 \u03bcg) a\u015f\u0131s\u0131 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklarda COVID-19 hastal\u0131\u011f\u0131 riskini yakla\u015f\u0131k y\u00fczde 90 oran\u0131nda azaltm\u0131\u015ft\u0131r. Klinik \u00e7al\u0131\u015fmalarinda, Moderna’n\u0131n Spikevax\u00ae (50 \u03bcg) a\u015f\u0131s\u0131 da 6 ila 11 ya\u015flar\u0131nda koronavir\u00fcs enfeksiyonlar\u0131n\u0131 \u00f6nlemede yakla\u015f\u0131k y\u00fczde 76’l\u0131k y\u00fcksek bir etkinlik elde etmi\u015ftir.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    \u00c7ocuk a\u015f\u0131lar\u0131 vir\u00fcs varyantlar\u0131na kar\u015f\u0131 iyi koruma sa\u011fl\u0131yor mu?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    BioNtech\/Pfizer’den \u00e7ocuklar i\u00e7in uyarlanan a\u015f\u0131ya ili\u015fkin yeni g\u00f6zlemsel veriler, \u015fu anda bask\u0131n olan omikron varyant\u0131 ile enfeksiyonlara kar\u015f\u0131 koruyucu etkide \u00f6nemli bir azalma oldu\u011funu g\u00f6stermektedir. Ancak: A\u015f\u0131n\u0131n ciddi hastal\u0131klara kar\u015f\u0131 iyi bir koruma sa\u011flamaya devam etti\u011fi de a\u00e7\u0131kt\u0131r. Koruyucu etki, muhtemelen azalt\u0131lm\u0131\u015f dozaj nedeniyle 5 ila 11 ya\u015f\u0131ndakilerde genel olarak daha d\u00fc\u015f\u00fckt\u00fcr ve 12 ila 17 ya\u015f\u0131ndakilere g\u00f6re daha \u00e7abuk ge\u00e7er.<\/p>

    Bununla birlikte, 5 ila 11 ya\u015f grubundaki y\u00fcksek enfeksiyon insidans\u0131 nedeniyle, \u00e7ocuklar\u0131n \u00e7o\u011funda a\u015f\u0131lama yoluyla bir ba\u015fka deyimle hibrit ba\u011f\u0131\u015f\u0131kl\u0131k olu\u015fturulabilir, yani bir koronavir\u00fcs enfeksiyonundan do\u011fal olarak elde edilen koruma ve a\u015f\u0131 arac\u0131l\u0131 koruman\u0131n bir kombinasyonu. Uzmanlar, bu kombinasyonun, bug\u00fcne kadar bilinen vir\u00fcs varyantlar\u0131na sahip enfeksiyonlara kar\u015f\u0131 tek ba\u015f\u0131na enfeksiyon veya a\u015f\u0131lamaya g\u00f6re daha iyi koruma sa\u011flad\u0131\u011f\u0131n\u0131 varsay\u0131yorlar. STIKO’ya g\u00f6re, daha geni\u015f bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi sayesinde, yeni vir\u00fcs varyantlar\u0131na kar\u015f\u0131 daha iyi koruma sa\u011flanmas\u0131 m\u00fcmk\u00fcn olabilir.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t5-11 ya\u015f aras\u0131ndaki sa\u011fl\u0131kl\u0131 \u00e7ocuklar neden sadece bir kez a\u015f\u0131lanmal\u0131d\u0131r?\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Tek seferlik korona a\u015f\u0131s\u0131 ile \u00e7ocuklar, korona vir\u00fcs\u00fcne kar\u015f\u0131 temel bir ba\u011f\u0131\u015f\u0131kl\u0131k geli\u015ftirerek vir\u00fcs\u00fc daha h\u0131zl\u0131 tan\u0131yabilir ve ard\u0131ndan onunla ba\u015far\u0131l\u0131 bir \u015fekilde m\u00fccadele edebilir. A\u015f\u0131lama spike proteine \u200b\u200bkar\u015f\u0131 bir ilk ba\u011f\u0131\u015f\u0131kl\u0131k tepkisine yol a\u00e7ar. Daha sonra gerekli olmas\u0131 halinde (\u00f6rne\u011fin, hastal\u0131\u011f\u0131n ciddiyeti yeni veya yeniden dola\u015f\u0131mdaki vir\u00fcs varyantlar\u0131 nedeniyle belirtilmi\u015fse) daha sonraki bir tarihte ba\u015fka bir a\u015f\u0131 ile derhal g\u00fc\u00e7lendirilebilir.<\/p>

    Yeti\u015fkinlerden elde edilen veriler ayr\u0131ca, iki birincil (temel) a\u015f\u0131lama dozu aras\u0131nda daha uzun bir aral\u0131\u011f\u0131n daha y\u00fcksek etkinlikle sonu\u00e7lanabilece\u011fini g\u00f6stemektedir. Bu nedenle ve olas\u0131 yeni bir enfeksiyon dalgas\u0131n\u0131 (\u00f6rne\u011fin \u00f6n\u00fcm\u00fczdeki sonbaharda\/k\u0131\u015fta) g\u00f6z \u00f6n\u00fcnde bulundurarak STIKO, 5 ila 11 ya\u015f\u0131ndaki t\u00fcm \u00e7ocuklar\u0131n yaz aylar\u0131nda bir kerelik a\u015f\u0131 olmalar\u0131n\u0131 \u00f6nermektedir. Bu \u015fekilde, y\u0131l sonunda salg\u0131n durumu veya yeni bilimsel bulgular nedeniyle ba\u011f\u0131\u015f\u0131kl\u0131k korumas\u0131n\u0131 optimize etmek i\u00e7in ek bir a\u015f\u0131lama ihtiyac\u0131 ortaya \u00e7\u0131karsa, m\u00fcmk\u00fcn olan en uzun a\u015f\u0131lama aral\u0131\u011f\u0131 elde edilebilir.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Yan etkileri nelerdir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    \u015eimdiye kadar g\u00f6zlemlenen a\u015f\u0131 reaksiyonlar\u0131 genellikle hafif \u00a0ve 12 ya\u015f\u0131ndan b\u00fcy\u00fck ergenler ve yeti\u015fkinler ile kar\u015f\u0131la\u015ft\u0131r\u0131labilir \u015fekildedir. Raporlar, enjeksiyon b\u00f6lgesinde a\u011fr\u0131, k\u0131zar\u0131kl\u0131k ve \u015fi\u015flik, yorgunluk ve ba\u015f a\u011fr\u0131s\u0131n\u0131 i\u00e7erir.<\/p>

    Spesifik olarak, bu \u015fu anlama gelir: Comirnaty\u00ae 10 \u00b5g onay \u00e7al\u0131\u015fmas\u0131nda en yayg\u0131n yan etkiler enjeksiyon b\u00f6lgesinde a\u011fr\u0131 (y\u00fczde 80), yorgunluk \/ bitkinlik (y\u00fczde 50), ba\u015f a\u011fr\u0131s\u0131 (y\u00fczde 30), enjeksiyon yerinde k\u0131zar\u0131kl\u0131k ve \u015fi\u015flik (y\u00fczde 20),\u00a0 ve uzuvlarda a\u011fr\u0131 (y\u00fczde 10). Semptomlar genellikle hafif ila orta \u015fiddettedir ve a\u015f\u0131dan sonraki birka\u00e7 g\u00fcn i\u00e7inde azal\u0131r. STIKO\u2019ya g\u00f6re, Corminaty\u00ae<\/sup> ile a\u015f\u0131lamadan sonra kalp kas\u0131nda \u00e7ok nadir iltihaplanma (miyokardit) riski, 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklarda ergenlere ve gen\u00e7 yeti\u015fkinlere g\u00f6re \u00f6nemli \u00f6l\u00e7\u00fcde daha d\u00fc\u015f\u00fckt\u00fcr.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    G\u00fcncellik: 06.2022,<\/em> Kaynak: Bundesministerium f\u00fcr Gesundheit<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    5 ila11 ya\u015f\u0131ndaki \u00e7ocuklar i\u00e7in Korona A\u015f\u0131s\u0131 Neden 5 ila 11 ya\u015f\u0131ndaki \u00e7ocuklar da a\u015f\u0131lanmal\u0131d\u0131r? Kas\u0131m 2021’de BioNTech\/Pfizer’in COVID-19 a\u015f\u0131s\u0131 AB genelinde 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklar i\u00e7in daha d\u00fc\u015f\u00fck bir dozda onaylanm\u0131\u015ft\u0131. Ba\u015flang\u0131\u00e7ta \u00e7ocuk a\u015f\u0131s\u0131 Daimi A\u015f\u0131 Komisyonu (STIKO) taraf\u0131ndan daha \u00e7ok \u00f6nceden hastal\u0131\u011f\u0131 olan \u00e7ocuklar i\u00e7in tavsiye etmi\u015fti. \u015eimdi STIKO 5 ya\u015f\u0131ndan […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/6732"}],"collection":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/comments?post=6732"}],"version-history":[{"count":38,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/6732\/revisions"}],"predecessor-version":[{"id":8376,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/6732\/revisions\/8376"}],"wp:attachment":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/media?parent=6732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}